ReviewCentral European journal of urology2014
Management and follow up of extra-adrenal phaeochromocytoma.
Review in Central European journal of urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Pheochromocytoma and Adrenocortical Carcinoma: Morphological Characteristics in Endoscopic Ultrasound Imaging.Ultrasound international open · 2021Article
- Diagnosis and surgical treatment of retroperitoneal paraganglioma: A single-institution experience of 34 cases.Oncology letters · 2017Article
- The role of miRNAs in the pheochromocytomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Acute coronary syndrome: a rare case of multiple endocrine neoplasia syndromes with pheochromocytoma and medullary thyroid carcinoma.Cancer biology & medicine · 2015Article
- Spectrum of retroperitoneal and genitourinary paraganglioma: Experience at a North Indian tertiary care center.Central European journal of urology · 2015Article
- [Perioperative management of a retroperitoneal paraganglioma].The Pan African medical journal · 2015Article
- Preliminary experience of the robot-assisted laparoscopic excision of a retroperitoneal mass: A case report.Oncology letters · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe prevalence of phaeochromocytoma (PCC) in patients with hypertension is 0.1-0.6% and about 10% of PCCs are detected in extra-adrenal tissue. The diagnosis and therapy of this rare disease detected as a retroperitoneal tumor mass can be difficult for clinicians. MATERIAL AND
methodsA PubMed database was searched for the peer-reviewed articles, the listed articles until Dec 2012 were included. Following key words were used: "extra-adrenal phaeochromocytoma", "paraganglioma", "diagnosis", "therapy", "surgery", "genetic analysis", and "SDH mutation".
resultsMagnetic Resonance Imaging (MRI) and Computed Tomography (CT) are first choice imaging tools for PCC (sensitivity 90-100%). For the validation of the diagnosis or follow up, the functional imaging 123I-metaiodobenzylguanidine (MIBG) or Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (excellent specificity and sensitivity of 90-100% in detection of small tumors >1-2 cm) are used. Laparoscopic surgery with complete resection is a safe and a first choice approach. The conversion (about 5%) to direct open operation was needed for large lesions (>8 cm) with the suspicion of malignancy. Currently, there are no histological criteria for distinguishing benign and malignant tumors. The genetic testing (Sanger DNA sequencing) for hereditary syndromes (von Hippel-Lindau, neurofibromatosis, etc.) is used for prediction of malignancy and recurrence. All patients should get individual and risk-adapted genetic analysis and consultation, including family members. The rate of malignancy in ePCC is about 30% (PCC about 5-10%). In patients with proven SDHB germline mutations, higher malignancy rate, multiple PCCs and recurrences are likely. A stringent lifelong clinical follow-up is recommended in these cases. Patients with syndromic hereditary forms should be screened for other often associated neoplasms.
conclusionsNew imaging tools and genetic analysis are crucial to improve the diagnosis and prognosis of phaeochromocytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.